Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
initial US approval 2022, paediatric T2D label updateTier 1 primary [3]NICE TA924: tirzepatide for treating type 2 diabetes (published 25 October 2023, updated 1 September 2025)Tier 1 primary [4]NICE TA1026: tirzepatide for managing overweight and obesity (published 23 December 2024, updated 1 September 2025)Tier 1 primary [5]Jastreboff et al
Disclaimer: The information provided in this article is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment
Taurochenodeoxycholic acid reduces astrocytic neuroinflammation and alleviates experimental autoimmune encephalomyelitis in mice
Disruption of SUMOylation has been implicated in AD, HD and PD, where it contributes to protein aggregation, synaptic dysfunction, and neuronal vulnerability
US$ 20.94
US$ 25.90
US$ 26.96
US$ 26.10
US$ 21.63
US$ 24.70
US$ 26.87
